​EIT Health UK and Ireland CoLocation Centre (UKI CLC) Application for Headstart

Summary
The European Institute of Innovation and Technology (EIT) is an independent body of the European Union set up to spur innovation and entrepreneurship across Europe to overcome some of its greatest challenges. 
 
As part of its “Accelerator” activities, EIT Health provides funding for emerging companies and SMEs to develop new products and services for areas of interest to EIT Health and its members. The purpose of the funding is to accelerate market entry and create new economic activity and applications to support research will be rejected. Seven awards of up to 50K€ are available and funds must be spent by 31st December 2016.

Proof of concept funding is suitable for individuals and organisations that have a well- developed prototype and are ready to launch a product. Applications will be accepted from organisations that are not yet incorporated as companies but we will expect that a company will be formed within six months of the funding

Headstart funding is open to established companies that are already trading in the UK and Ireland but wish to explore new markets.

Priority areas

The UKI CLC is now seeking applications from companies and individuals based in the UK and Ireland in the following challenge areas defined by our industry partners as follows:
  1. P&G Challenge: Innovation in consumer products
  2. IBM & Pfizer Challenge: Novel Solutions for Improving Medication Adherence
  3. Pfizer Challenge: New Solutions to Facilitate Chronic Disease Management
  4. “Wild Card” Challenge
Benefits: In addition to the 50K€ our industry partners will provide access to innovation facilities and networks as well as mentorship to successful applicants.

More information can be found here

Deadline: Proposals must be received by noon on Tuesday 31st May 2016. Applicants should provide a completed application form and a video pitch by email to paddie.murphy@wmahsn.org. Please note, word limits must be strictly adhered to; any sections that exceed the word count will be excluded.

Evaluation: Proposals will be reviewed by a team of experts drawn from the UKI CLC and representatives of local VCs and confidentiality agreements will be in place. Successful proposals will be those that provide a compelling case for the use of the funding to accelerate the route to market.

Key performance indicators (KPIs): Successful proposals will be expected to deliver one or more of the following KPIs:
  •   Business ideas incubated and progressed to market
  •   Start-ups or spin off companies created
  •   Products or services launched
  •   New markets accessed
  •   Jobs created. 

Block